

**Anti-DLL3 Reference Antibody (rovalpituzumab)
Recombinant Antibody
Catalog # APR10108**

Specification

Anti-DLL3 Reference Antibody (rovalpituzumab) - Product Information

Application	FC, E, FTA
Primary Accession	O9NYJ7
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.02 KDa

Anti-DLL3 Reference Antibody (rovalpituzumab) - Additional Information

Target/Specificity
DLL3

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-DLL3 Reference Antibody (rovalpituzumab) - Protein Information

Name DLL3

Function
Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity).


Cellular Location
Membrane; Single-pass type I membrane protein

Anti-DLL3 Reference Antibody (rovalpituzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-DLL3 Reference Antibody (rovalpituzumab) - Images




Anti-DLL3 Reference Antibody (rovalpituzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-DLL3 Reference Antibody (rovalpituzumab) is more than 98.44% ,determined by SEC-HPLC.



Immobilized human DLL3 His at 2 µg/mL can bind Anti-DLL3 Reference Antibody (rovalpituzumab) EC50=0.01407 µg/mL



Human DLL3 HEK293 cells were stained with Anti-DLL3 Reference Antibody (rovalpituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC161=0.01586 µg/mL